Short Interest Report: Acadia Pharmaceuticals Incorporated (NASDAQ:ACAD) Stock Is Shorted More

November 23, 2016 - By Dolores Ford   ·   0 Comments

Short Interest Report: Acadia Pharmaceuticals Incorporated (NASDAQ:ACAD) Stock Is Shorted More

The stock of Acadia Pharmaceuticals Incorporated (NASDAQ:ACAD) registered an increase of 6.75% in short interest. ACAD’s total short interest was 20.68 million shares in November as published by FINRA. Its up 6.75% from 19.37M shares, reported previously. With 2.77M shares average volume, it will take short sellers 8 days to cover their ACAD’s short positions. The short interest to Acadia Pharmaceuticals Incorporated’s float is 23.22%. About 5,075 shares traded hands. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) has declined 20.69% since April 21, 2016 and is downtrending. It has underperformed by 26.02% the S&P500.

ACADIA Pharmaceuticals Inc. is a biopharmaceutical company. The company has a market cap of $3.02 billion. The Firm is focused on the development and commercialization of medicines for central nervous system disorders. It currently has negative earnings. The Company’s lead drug candidate, NUPLAZID , is under development for the treatment of Parkinson’s disease psychosis (PDP).

Insitutional Activity: The institutional sentiment increased to 1.2 in Q2 2016. Its up 0.18, from 1.02 in 2016Q1. The ratio increased, as 32 funds sold all ACADIA Pharmaceuticals Inc. shares owned while 68 reduced positions. 41 funds bought stakes while 61 increased positions. They now own 104.57 million shares or 4.71% less from 109.74 million shares in 2016Q1.
Laurion Cap Mngmt L P owns 112,100 shares or 0.06% of their US portfolio. Eagle Asset Mngmt Inc has invested 0.21% of its portfolio in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD). Aperio Grp Ltd Limited Liability Company owns 17,797 shares or 0% of their US portfolio. Stifel Fincl holds 11,066 shares or 0% of its portfolio. Reilly Finance Limited Co has 0% invested in the company for 425 shares. Moreover, Sivik Healthcare Limited Liability Co has 0.93% invested in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) for 57,500 shares. Fmr Llc has invested 0.08% of its portfolio in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD). Amer Century Companies last reported 10,468 shares in the company. Hollencrest Securities Ltd Com last reported 12,602 shares in the company. Great West Life Assurance Can last reported 9,295 shares in the company. Capital Fincl Advisers Ltd Co holds 12,767 shares or 0% of its portfolio. Alliancebernstein Limited Partnership holds 0% or 134,270 shares in its portfolio. Deutsche National Bank & Trust Ag accumulated 1.35 million shares or 0.03% of the stock. Tci Wealth Inc last reported 1,400 shares in the company. Hanseatic Mgmt Services Inc reported 31,025 shares or 0.38% of all its holdings.

Insider Transactions: Since July 11, 2016, the stock had 2 buys, and 2 selling transactions for $42.17 million net activity. 1,000 ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) shares with value of $32,970 were bought by HARRIGAN EDMUND. Baity Glenn had sold 10,200 shares worth $306,687. $43.00M worth of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) was bought by BAKER BROS. ADVISORS LP on Wednesday, August 10.

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Ratings Coverage

Out of 7 analysts covering ACADIA Pharmaceuticals (NASDAQ:ACAD), 4 rate it a “Buy”, 0 “Sell”, while 3 “Hold”. This means 57% are positive. ACADIA Pharmaceuticals has been the topic of 16 analyst reports since August 7, 2015 according to StockzIntelligence Inc. The stock of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) earned “Overweight” rating by Piper Jaffray on Friday, August 7. The firm has “Market Perform” rating given on Tuesday, May 3 by Leerink Swann. JP Morgan maintained ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) on Friday, September 4 with “Buy” rating. Vetr upgraded the stock to “Hold” rating in Monday, August 10 report. Piper Jaffray upgraded ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) on Friday, January 22 to “Overweight” rating. The stock of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) has “Buy” rating given on Friday, August 7 by Needham. Cowen & Co maintained the stock with “Outperform” rating in Sunday, August 9 report. Roth Capital reinitiated ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) on Wednesday, October 19 with “Neutral” rating. The company was initiated on Tuesday, October 4 by Leerink Swann. The rating was upgraded by Bank of America to “Buy” on Tuesday, November 8.

ACAD Company Profile

ACADIA Pharmaceuticals Inc., incorporated on January 16, 1997, is a biopharmaceutical company. The Firm is focused on the development and commercialization of medicines for central nervous system disorders. The Company’s lead drug candidate, NUPLAZID (pimavanserin), is under development for the treatment of Parkinson’s disease psychosis (PDP).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Dolores Ford


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>